Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mu-opioid antagonism in the treatment of cannabis use disorder

Literature DB >> 32096619

Mu-opioid antagonism in the treatment of cannabis use disorder

Oussama Kebir¹, Xavier Laqueille¹, Fayçal Mouaffak¹.

Abstract

Year: 2020 PMID： 32096619 PMCID： PMC7828912 DOI： 10.1503/jpn.190182

Source DB: PubMed Journal: J Psychiatry Neurosci ISSN： 1180-4882 Impact factor: 6.186

Keyword Cloud
References

× No keyword cloud information.

13 in total

1. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents.

Authors: Suzanne Nielsen; Pamela Sabioni; Linda Gowing; Bernard Le Foll
Journal: Handb Exp Pharmacol Date: 2020

2. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

Authors: Mohini Ranganathan; Michelle Carbuto; Gabriel Braley; Jaqueline Elander; Edward Perry; Brian Pittman; Rajiv Radhakrishnan; Richard A Sewell; Deepak C D'Souza
Journal: Int J Neuropsychopharmacol Date: 2012-01-16 Impact factor: 5.176

Review 3. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Authors: Christina A Brezing; Frances R Levin
Journal: Neuropsychopharmacology Date: 2017-09-06 Impact factor: 7.853

4. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

Authors: Catalina Lopez-Quintero; José Pérez de los Cobos; Deborah S Hasin; Mayumi Okuda; Shuai Wang; Bridget F Grant; Carlos Blanco
Journal: Drug Alcohol Depend Date: 2010-12-08 Impact factor: 4.492

5. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

Authors: Margaret Haney; Divya Ramesh; Andrew Glass; Martina Pavlicova; Gillinder Bedi; Ziva D Cooper
Journal: Neuropsychopharmacology Date: 2015-04-16 Impact factor: 7.853

6. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors: Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal: Psychopharmacology (Berl) Date: 2003-12-11 Impact factor: 4.530

Mu-opioid antagonism in the treatment of cannabis use disorder

1. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents.

2. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

Review 3. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

4. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

5. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

6. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

7. Interaction between naltrexone and oral THC in heavy marijuana smokers.

8. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.

Review 9. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder.

10. Pharmacotherapies for cannabis dependence.